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A retrospective study of 87 patients diagnosed with the protozoan Dientamoeba fragilis
was performed due to a recent increase in the number of patients diagnosed with this
organism at the Unit of Clinical Parasitology, Huddinge University Hospital, Stockholm,
Sweden. Medical records were reviewed. The highest incidence was found in pre-school
boys, who also had the longest duration of symptoms, with a range of 1–630 weeks. A
majority of the patients had symptoms of diarrhea, abdominal pain and flatus. The
diarrhea varied from watery to loose, blood being reported only sporadically. Most
patients had traveled outside Europe and had no other parasites in their stools. This
study indicates potential pathologic properties in D. fragilis, and prospective studies are
recommended.
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Dientamoeba fragilis was discovered in 1909, and
reported as a new species by Jepps and Dobell in
1918 [1]. The protozoan has a cosmopolitan dis-
tribution [2] and has been found in humans and
monkeys [3]. It is now classified as a flagellate, as it
shows ultrastructural and antigenic resemblance
to Trichomonas and Histomonas [4]. It infects the
whole colon from cecum to rectum. This protozoan
has no cyst form but can be readily detected as a
trophozoite. The mode of transmission is so far
unknown, although fecal–oral transmission or the
existence of a vector, possibly Enterobius vermicu-
laris (pin worm), have been proposed [5,6]. It has
been debated whether D. fragilis should be con-
sidered as a pathogen, despite recent studies sup-
porting its pathogenic role [7]. Owing to an
increase in the numbers of patients diagnosed with
this protozoan at the Unit of Clinical Parasitology,
Huddinge University Hospital, Stockholm, Swe-
den since 1996, an analysis of the patients was
performed. The purpose was to describe symp-
toms, clinical findings, treatment and outcome in
the infected patients.
Eighty-seven patients diagnosed with D. fragilis
at the Unit of Clinical Parasitology Laboratory,
Huddinge University Hospital, Stockholm, Sweden
during the year 2000 were followed up. Clinical
and laboratory findings were recorded. The stool
samples (usually one per patient) were sent in to the
laboratory sodium acetate–acetic acid–formalin
solution. The modified Ritchie fecal concentration
technique was used. The laboratory identification
of D. fragilis was made by light microscopy and
with staining (Trichrome; prepared by the labo-
ratory) as the next step [8]. All parasites detected
in these samples were reported, including Cryp-
tosporidium and Cyclospora. Bacterial infections
detected by stool culture were registered, but
examination for viruses was not performed.
Forty-four of the subjects were female and 43
were male, their ages ranging from 1 to 77 years.
Nineteen of the 43 males were less than 10 years of
age, while there was little variation in incidence
between the age groups among the females. Nine
females were less than 10 years of age (Figure 1,
Table 1).
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Sixty-three per cent of the patients were likely to
have been infected with D. fragilis outside Sweden.
Forty-two per cent were reportedly infected out-
side Europe. Of the 23% infected within Europe,
8% were certainly infected in Sweden. Most
patients were infected in Africa, South America
and the Middle East.
Twenty-four per cent of the patients had findings
of other parasites or bacteria in their stool samples.
Giardia intestinalis and Entamoeba coli were the most
frequently found parasites (Table 1). Two patients
had Enterobius vermicularis in the stool samples.
Thirty of the 87 patients had results of blood
tests measuring white blood cells, hemoglobin and
C-reactive protein performed in association with
the D. fragilis infection. None of the tested patients
had any pathologic values in these tests.
The most frequent symptoms were abdominal
pain, diarrhea, flatus, fatigue and overall looseness
of stools (Table 2). Nausea, weight loss and vomit-
ing were also found. Two patients were asympto-
matic, and in six patients clinical symptoms were
not recorded. The asymptomatic patients had stool
samples taken as part of a routine medical exam-
ination. Five of the six patients with no symptoms
were individuals seeking asylum for personal or
political reasons.
Nineteen patients were reported to suffer from
intolerance of lactose. One boy reported feeling
worse after eating his yoghurt breakfast and other
lactose products. However, none of the patients
with similar complaints improved after excluding
lactose from their diets. Sixteen patients, two of
whom were women, were subjected to clinical
Figure 1 Prevalence of D. fragilis in
different age groups.
Table 1 Bacteria and parasites found in 21 patients with D.
fragilis infection
Organism Number
Bacteria
Campylobacter 3
Shigella 2
Salmonella 2
Aeromonas caviae 1
Parasites
Blastocystis hominis 9
Entamoeba coli 7
Giardia intestinalis 4
Enterobius vermicularis 2
Trichuris trichiuria 2
Entamoeba hartmanni 1
Endolimax nana 1
Trichomonas 1
Table 2 Symptoms in 79 patients with D. fragilis infection
Symptom Number
Diarrhea 33
Abdominal pain 33
Loose stools 27
Sensitivity to lactosea 19
Flatus 17
Fatigue 16
Vomiting 10
Anal itching 8
Fever 8
Reduced control over bowel 6
Nausea 5
Anorexia 5
Cramps 5
Weight loss 4
Mucus or blood in stool 4
aAs perceived by patients.
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lactose intolerance tests. Two males were diag-
nosed with lactose intolerance.
Patients who were symptomatic had a duration
of symptoms lasting between 1 and 630 weeks. The
most important factors influencing the duration
appeared to be sex and age. The duration was by
far the longest in males, particularly in those under
10 years of age. A small peak of increased duration
is found in males around the age of 40 years. The
longest duration in women was found in patients
infected during childhood, the childbearing years
or after the menopause. In all age groups, males
had a longer duration of symptoms.
Thirty-two patients infected with only the pro-
tozoan were treated with metronidazole. The drug
was given at various dosages and for various
lengths of time, but no correlation was found
between dosage or length of treatment and clinical
success. Four patients recovered after the metro-
nidazole treatment, while 12 patients had recur-
ring or reduced symptoms.
The present study shows that a cohort of
patients diagnosed with D. fragilis suffered from
clinical symptoms. These patients were in many
cases puzzling to the clinicians, especially within
the field of pediatric medicine. To date, the patho-
genicity of this protozoan remains unconfirmed,
despite recent studies seeming to indicate that D.
fragilis has pathogenic properties [7,9–11]. Also,
genetic diversity has been described in D. fragilis,
implying the possible existence of pathogenic and
non-pathogenic variants [12]. The absence of other
pathogenic microorganisms in the stools of most
patients in the present study supports the patho-
genicity of D. fragilis. D. fragilis is known to be a
cosmopolitan parasite [7,10]. In this study, the
majority of the patients were abroad at the time
of infection.
The mode of transmission of D. fragilis is still
under debate. Theories concerning fecal–oral as
well as vector-borne transmission have been pre-
sented [9,11]. The finding that a majority of
patients had no other microorganisms isolated
in their stools suggests that these patients had
not been in close contact with water of poor
hygienic standard. It could also strengthen the
theory of a vector being involved in the transmis-
sion of D. fragilis. The high frequency of anal
itching might be a symptom of infection with
Enterobius vermicularis. However, the frequency
of coexistence does not surpass that of D. fragilis
with Blastocystis hominis. As pointed out by Preiss
et al. [7], infection with Enterobius vermicularis can
be resolved independently of D. fragilis infection.
The peak incidence was found in pre-school
boys, and this finding is in contrast to previous
studies [9], where the highest prevalence was
found in young girls. The reason might be the be-
havior of this age and sex cohort. Whether the size
or frequency of the infectious dose is of principal
importance is unclear. It was not possible in this
study to verify whether the children attended day-
care centers, but our assumption is that the major-
ity did (as this is the norm in Sweden). Close
contact and crowding could be of importance for
transmission, as mentioned by Windsor et al. [10].
The prolonged duration of symptoms in boys could
again be dependent on the size of the dose, or the
frequency of reinfection. Many patients reported
having symptomatic family members, and the
range of duration was significant (1–630 weeks).
In accordance with previous reports [7,9,10,13],
the most commonly found symptoms were
abdominal pain, loose stools or diarrhea, flatu-
lence, anorexia, and fatigue. As these are well
documented, it is of importance that fecal sam-
pling becomes part of the routine investigation of
this symptomatology.
The high number of patients tested for lactose
intolerance may be due to frequent misinterpreta-
tion of the symptoms caused by D. fragilis. Though
many patients reported feeling worse after all
ingestion, both doctors and patients often sus-
pected lactose intolerance, and tests for lactose
intolerance were performed before parasitic infec-
tion was excluded.
In this study, the clinical effect of metronidazole
was moderate, while Preiss et al. [7] reported a
70% success rate of 10-day metronidazole treat-
ment. When this treatment was followed by oxy-
tetracycline, the success rate rose to 90%.
Indications of doubtful effects of treatment, and
of severe long-term health effects, emphasize the
necessity for more thorough prospective studies of
D. fragilis.
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